Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Jacksonville, Florida

This page shows live ClinicalTrials.gov search results for Jacksonville, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7646
Shown on this page
12
Current sort
Recently updated
Location scope
Jacksonville, FL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Jacksonville, Florida. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 673–684 of 7,646 matching trials in Jacksonville, FL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Jacksonville

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

NCT07300839
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 Vaccine, Placebo
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
50 Years to 64 Years
Enrollment
5,240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
196
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Active, not recruiting Not applicable Interventional

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

NCT05198674
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions
Renal Denervation (Symplicity Spyral™)
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
76
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Recruiting Phase 3 Interventional

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875
View directory record Official record
Conditions
HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions
Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, 5-fluorouracil, Capecitabine, Cisplatin, Oxaliplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
58
States / cities
Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Enrolling by invitation Phase 3 Interventional

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT05979441
View directory record Official record
Conditions
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Beverly Hills, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients

NCT02922036
View directory record Official record
Conditions
Heart Failure
Interventions
WiSE System
Device
Lead sponsor
EBR Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
43
States / cities
Huntsville, Alabama • La Jolla, California • Fort Lauderdale, Florida + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Active, not recruiting Phase 3 Interventional

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
216
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Active, not recruiting Phase 3 Interventional

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Recruiting Phase 3 Interventional

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

NCT07431281
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
Interventions
Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil, Oxaliplatin, Zolbetuximab, Leucovorin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
93
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 81 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Recruiting Not applicable Interventional

Evaluating the Efficacy of a "Quiet Knee Protocol" in Primary Total Knee Arthroplasty (TKA): A Prospective Randomized Study

NCT07879014
View directory record Official record
Conditions
Rehabilitation Exercise
Interventions
Quiet Knee Protocol, Post Operative Standard of Care
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Jacksonville, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Recruiting Not applicable Interventional

NORM-HF Pivotal Study

NCT07574593
View directory record Official record
Conditions
Heart Failure, NYHA Class III Heart Failure, NYHA Class II Heart Failure
Interventions
IVC Sensor
Device
Lead sponsor
Foundry Innovation & Research 1, Limited (FIRE1)
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
25
States / cities
Chula Vista, California • Sacramento, California • Jacksonville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Recruiting Phase 2Phase 3 Interventional

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

NCT06328777
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma, Interstitial Lung Diseases
Interventions
CABA-201
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
New Haven, Connecticut • Jacksonville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

NCT06389136
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 63 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 15, 2026, 5:17 AM EST